Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's glipizide and
metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets
following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting
conditions.